Compare · STIM vs WST
STIM vs WST
Side-by-side comparison of Neuronetics Inc. (STIM) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both STIM and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $25.31B, about 224.5x STIM ($112.7M).
- Over the past year, STIM is down 55.6% and WST is up 69.7% - WST leads by 125.3 points.
- WST has been more active in the news (5 items in the past 4 weeks vs 4 for STIM).
- WST has more recent analyst coverage (18 ratings vs 4 for STIM).
- Company
- Neuronetics Inc.
- West Pharmaceutical Services Inc.
- Price
- $1.62-9.24%
- $358.18-1.11%
- Market cap
- $112.7M
- $25.31B
- 1M return
- +33.33%
- +8.72%
- 1Y return
- -55.62%
- +69.72%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 4
- 5
- Recent ratings
- 4
- 18
Neuronetics Inc.
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest STIM
- Large owner Chernett Jorey bought $62,300 worth of shares (35,000 units at $1.78), increasing direct ownership by 0.33% to 10,588,988 units (SEC Form 4)
- New insider Anderson Cory claimed ownership of 416,812 shares (SEC Form 3)
- Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026
- SEC Form 8-K filed by Neuronetics Inc.
- Director Amin Avinash disposed of 42,500 shares, decreasing direct ownership by 59% to 30,000 units (SEC Form 4)
- Large owner Madryn Asset Management, Lp acquired 72,500 shares (SEC Form 4)
- Neuronetics Appoints Robert Greene as Senior Vice President Sales
- SEC Form SD filed by Neuronetics Inc.
- Director Rosengarten Megan was granted 30,000 shares, increasing direct ownership by 21% to 170,890 units (SEC Form 4)
- Director Muir Glenn P was granted 30,000 shares, increasing direct ownership by 8% to 401,816 units (SEC Form 4)
Latest WST
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits